What is AIM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AIM?

P/E (TTM) is n/a and 52-week range is $0.17 to $2.79 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AIM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AIM?

The company profile lists revenue (TTM) near $152K, net income (TTM) near $-2.29B, EPS (TTM) near $-3.93 when available from the market-data feed. Figures are informational and may lag live markets.

Where is AIM ImmunoTech Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Ocala, Florida, US, 27.7M shares outstanding, ISIN US00901B3033 when available from company profile and filing metadata.

AIM ImmunoTech Inc

$AIM

Health Care · Biotechnology

IR Run Scenarios

$0.18

+0.22%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 19 full-time employees. The firm is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Employees

Website

aimimmuno.com/

IPO

1996-07-12

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)